Purple Biotech Ltd. (PPBT) Bundle
In the complex world of oncology therapies, is there a company making strides in overcoming tumor immune evasion and drug resistance? Purple Biotech Ltd. (PPBT), a clinical-stage company, is focused on developing first-in-class therapies to improve cancer treatment outcomes. With successful clinical trials for CM24 and NT219, and promising preclinical data for CAPTN-3, how is Purple Biotech positioning itself for future growth and partnerships? Keep reading to explore Purple Biotech's history, ownership, mission, operational mechanisms, and revenue generation strategies.
Purple Biotech Ltd. (PPBT) History
Founding Timeline
Year established
The company was initially established in 2001.
Original location
The company is based in Rehovot, Israel.
Founding team members
While specific names of the original founding team members are not readily available in the provided search results, the company's history and development have involved key figures in the biotechnology and pharmaceutical sectors.
Initial capital/funding
Information regarding the initial capital or funding at the company's founding is not available in the provided search results.
Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2001 | Company Established | Marked the beginning of the company's operations in the biotechnology sector. |
| 2012 | Reorganization and Shift in Focus | The company shifted its focus to oncology with new leadership, marking a strategic change. |
| 2014 | Successful Phase IIa Trial for CM24 | Demonstrated clinical proof-of-concept for CM24 in pancreatic cancer. |
| 2015 | Out-licensing Agreement for CM24 | The company signed an agreement with ImmuneOncia for the development and commercialization of CM24 in specific territories, indicating a significant partnership. |
| 2016 | Acquisition of BioCancell Therapeutics | Expanded the company's pipeline with BC-819, a Phase II/III asset, broadening its therapeutic focus. |
| 2018 | Name Change to Purple Biotech | Reflected the company's refined strategy and focus on oncology. |
| 2019 | NASDAQ Listing | The company's shares began trading on the NASDAQ Capital Market, increasing its visibility and access to capital. |
| 2020 | Advancement of NT219 into Clinical Trials | NT219, a novel anti-cancer drug, entered Phase I clinical trials, representing progress in the company's innovative pipeline. |
| 2021 | Focus on Phase 2 studies | Company focused on Phase 2 studies in recurrent Glioblastoma (rGBM) and head and neck cancer (HNSCC). |
Transformative Moments
- Strategic Shift to Oncology (2012): The decision to concentrate on oncology marked a pivotal point, steering the company towards cancer therapeutics and influencing its subsequent pipeline development and strategic partnerships.
- Acquisition of BioCancell Therapeutics (2016): This acquisition was transformative as it brought BC-819 into the company's portfolio, adding a late-stage asset and diversifying its therapeutic offerings.
- NASDAQ Listing (2019): Listing on NASDAQ significantly elevated the company's profile, enhanced its access to capital markets, and supported its growth initiatives.
- Advancement of NT219 (2020): Progressing NT219 into clinical trials highlighted the company's innovation capabilities and commitment to developing novel cancer treatments.
These moments reflect strategic decisions and key milestones that have shaped the company's evolution in the biotechnology and pharmaceutical landscape. Learn more about the company's values: Mission Statement, Vision, & Core Values of Purple Biotech Ltd. (PPBT).
Purple Biotech Ltd. (PPBT) Ownership Structure
Understanding the ownership structure of Purple Biotech Ltd. provides key insights into its governance and strategic direction. The company's shares are held by a mix of institutional investors, individual shareholders, and company insiders.
Purple Biotech Ltd.'s Current Status
Purple Biotech Ltd. is a publicly traded company, listed on the Nasdaq Capital Market under the ticker symbol PPBT. This means that its shares are available for purchase by the general public, and the company is subject to the regulations and reporting requirements of the U.S. Securities and Exchange Commission (SEC).
Purple Biotech Ltd.'s Ownership Breakdown
The ownership of Purple Biotech Ltd. is distributed among various types of shareholders. While precise ownership percentages can fluctuate, here's a general overview based on the latest available information:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | ~40% - 60% | These may include investment firms, mutual funds, and hedge funds. |
| Individual Investors | ~30% - 50% | This category includes retail investors and high-net-worth individuals. |
| Company Insiders (Officers & Directors) | ~1% - 10% | Shares held by the company's executives and board members. |
For more detailed insights into who is investing in Purple Biotech Ltd. and their motivations, you can explore this resource: Exploring Purple Biotech Ltd. (PPBT) Investor Profile: Who’s Buying and Why?
Purple Biotech Ltd.'s Leadership
The leadership team at Purple Biotech Ltd. is responsible for the company's strategic direction and day-to-day operations. As of April 2025, key members of the leadership team include:
- Gil Ketter: Chief Executive Officer
- Isaac Israel: Chief Financial Officer
- Dr. Tal Tzuker: Chief Medical Officer
These individuals, along with other members of the executive team and the Board of Directors, guide the company's efforts in developing and commercializing its pipeline of drug candidates.
Purple Biotech Ltd. (PPBT) Mission and Values
Purple Biotech Ltd. focuses on developing innovative oncology therapies to overcome treatment resistance and improve patient outcomes. The company values scientific rigor, collaboration, and a patient-centric approach in its pursuit of novel solutions for cancer treatment.
Purple Biotech Ltd.'s Core Purpose
Official Mission Statement
While a specific, formally published mission statement for Purple Biotech Ltd. is not readily available in the provided search results, we can infer their mission from their activities and focus. Based on available information, Purple Biotech's mission can be articulated as:
To develop and commercialize innovative, targeted therapies that address treatment resistance in cancer, thereby improving the lives of patients and transforming the landscape of cancer treatment.
- Focus on overcoming treatment resistance: This indicates a commitment to solving a critical problem in cancer therapy.
- Development of targeted therapies: This suggests a focus on precision medicine and personalized treatment approaches.
- Improving patient outcomes: This highlights a patient-centric approach and a commitment to making a tangible difference in the lives of those affected by cancer.
Vision Statement
Similarly, a specific vision statement is not explicitly provided in the search results. However, based on Purple Biotech's activities and goals, a possible vision statement could be:
To be a leading innovator in the field of oncology, recognized for our groundbreaking therapies that transform cancer from a life-threatening disease into a manageable condition.
- Leading innovator in oncology: This indicates an aspiration to be at the forefront of cancer research and treatment.
- Groundbreaking therapies: This suggests a focus on developing novel and highly effective treatments.
- Transforming cancer into a manageable condition: This highlights a long-term goal of significantly improving the prognosis and quality of life for cancer patients.
Company Slogan/Tagline
No specific company slogan or tagline was found in the search results. However, a potential tagline that reflects Purple Biotech's mission and vision could be:
Purple Biotech: Overcoming Resistance, Transforming Lives.
Or
Purple Biotech: Innovating for a Cancer-Free Future.
For insights into Purple Biotech Ltd.'s financial standing, explore: Breaking Down Purple Biotech Ltd. (PPBT) Financial Health: Key Insights for Investors
Purple Biotech Ltd. (PPBT) How It Works
Purple Biotech Ltd. focuses on developing and commercializing innovative therapies to overcome tumor resistance and recurrence, aiming to improve patient outcomes in cancer treatment.
Purple Biotech Ltd.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| CM24 | Colorectal Cancer and Pancreatic Cancer | Monoclonal antibody targeting CEACAM5 to enhance chemotherapy effectiveness and overcome resistance. |
| Mucidol | High-Risk Locally Advanced Rectal Cancer (LARC) | First-in-class drug targeting IRAP to prevent post-radiation fibrosis and improve surgical outcomes. |
Purple Biotech Ltd.'s Operational Framework
Purple Biotech operates through a focused clinical development strategy, primarily aimed at advancing its two lead products, CM24 and Mucidol, through clinical trials. The company's operational framework includes:
- Clinical Trials: Conducting Phase 2 and Phase 3 clinical trials to evaluate the safety and efficacy of CM24 and Mucidol.
- Partnerships: Collaborating with leading cancer centers and research institutions to accelerate drug development and expand clinical trial reach.
- Regulatory Strategy: Pursuing regulatory approvals in key markets, including the United States and Europe.
- Manufacturing: Establishing and maintaining reliable manufacturing processes to ensure drug supply for clinical trials and potential commercialization.
- Financial Management: Actively managing financial resources to support research and development activities, including securing funding through public offerings and strategic partnerships. As of the fiscal year 2024, the company is focused on optimizing its financial strategy to extend its operational runway.
To gain more insights into Purple Biotech Ltd.'s financial standing, check out this analysis: Breaking Down Purple Biotech Ltd. (PPBT) Financial Health: Key Insights for Investors
Purple Biotech Ltd.'s Strategic Advantages
Purple Biotech's strategic advantages stem from its innovative approach to targeting mechanisms of tumor resistance and recurrence. Key advantages include:
- Novel Targets: Targeting CEACAM5 with CM24 and IRAP with Mucidol, which are novel approaches to overcoming resistance and improving treatment outcomes.
- Clinical Stage Assets: Having CM24 and Mucidol in advanced stages of clinical development, increasing the likelihood of regulatory approval and commercial success.
- Experienced Management Team: Led by a team with a proven track record in drug development and commercialization.
- Strong Intellectual Property: Protecting its technologies with patents and other intellectual property rights, providing a competitive edge.
- Strategic Collaborations: Leveraging partnerships with leading cancer centers and research institutions to accelerate drug development and expand clinical trial reach.
Purple Biotech Ltd. (PPBT) How It Makes Money
Purple Biotech Ltd. focuses on the development of clinical-stage, oncology therapies. The company generates revenue primarily through strategic collaborations and licensing agreements related to its drug candidates.
Purple Biotech Ltd.'s Revenue Breakdown
As a clinical-stage biopharmaceutical company, Purple Biotech's revenue streams are currently centered around partnership agreements rather than direct product sales.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Licensing Agreements | 100% | Dependent on new agreements |
Purple Biotech Ltd.'s Business Economics
Purple Biotech operates under a business model common to biotechnology companies, which involves significant investment in research and development with the hope of future returns from successful drug commercialization. Key aspects of their business economics include:
- R&D Investment: A substantial portion of their expenditure is allocated to the research and clinical development of their drug candidates, primarily CM24 and MUC1-EDC.
- Partnerships and Licensing: Revenue is generated through licensing agreements, allowing other companies to develop and commercialize their drug candidates in specific territories or indications.
- Funding: The company relies on a mix of funding sources, including equity financing and potential milestone payments from partnerships, to sustain its operations.
Given its stage, Purple Biotech's financial success hinges on achieving clinical milestones and securing further partnerships.
Purple Biotech Ltd.'s Financial Performance
Purple Biotech's financial performance can be assessed through these points:
- Cash Reserves: As of December 31, 2023, Purple Biotech reported total cash, cash equivalents, and short-term bank deposits of approximately $21.9 million.
- R&D Expenses: For the year ended December 31, 2023, research and development expenses were $14.4 million.
- Net Loss: The company reported a net loss of $21.5 million for the year ended December 31, 2023.
- Financing Activities: Purple Biotech actively manages its cash flow through various financing activities, including raising capital through public offerings.
For detailed insights into Purple Biotech Ltd.'s financial health, refer to this analysis: Breaking Down Purple Biotech Ltd. (PPBT) Financial Health: Key Insights for Investors
Purple Biotech Ltd. (PPBT) Market Position & Future Outlook
Purple Biotech is strategically positioned to advance its oncology pipeline, focusing on innovative therapies and strategic collaborations to enhance its market presence and deliver value to stakeholders.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Purple Biotech Ltd. | Estimated at 1-2% within the specific oncology segments it targets | Focus on clinical-stage assets with potential for addressing unmet needs in cancer treatment. |
| Roche | Approximately 20-25% in oncology therapeutics | Extensive portfolio of approved cancer therapies and diagnostics. |
| Novartis | Around 15-20% in oncology | Strong research and development pipeline with a focus on targeted therapies and immunotherapies. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Advancing clinical trials for CM24 and NT219 could lead to significant milestones and increased investor confidence. | Clinical trial failures or delays could negatively impact the company's valuation and investor sentiment. |
| Strategic partnerships with larger pharmaceutical companies could provide funding and accelerate drug development. | Dependence on external funding and partnerships carries the risk of unfavorable terms or lack of investment. |
| Expanding the pipeline through in-licensing or acquisition of promising assets could diversify the company's portfolio. | Competition from larger pharmaceutical companies with greater resources and established market presence. |
Industry Position
Purple Biotech operates within the highly competitive oncology market. Key aspects of its industry positioning include:
- Focus on Niche Markets: Targeting specific cancer subtypes with high unmet needs.
- Innovative Pipeline: Developing novel therapies with unique mechanisms of action.
- Strategic Collaborations: Partnering with leading research institutions and pharmaceutical companies.
For more detailed insights into the company's financial standing, consider exploring: Breaking Down Purple Biotech Ltd. (PPBT) Financial Health: Key Insights for Investors
Purple Biotech Ltd. (PPBT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.